GlaxoSmithKline dba Human Genome Sciences Inc – FDA 483, Jul 31, 2025
The FDA inspection of Human Genome Sciences Inc. in Rockville, MD, revealed significant deficiencies across its quality control, equipment management, data integrity, and material control systems. The firm failed to adequately investigate excursions, manage out-of-service equipment, retain electronic data, verify critical component sterility, and establish proper procedures for sampling and labeling. These issues indicate a systemic lack of oversight and adherence to established procedures, potentially impacting the safety and quality of biological drug substances.
- Inspection date
- July 31, 2025
- Product type
- biologics
ID · 1bd342b5-73d7-4968-9da2-73fae2cb4d50
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.